Palabras claves: Bruton tyrosine kinase inhibitor, BTK, Ibrutinib, Lymphoma, PCNSL, Primary central nervous system lymphoma
Autores: Albert T., Bhagat R., Bhandari S., Bucheli D.H., Gajurel B.P., Joshi U., Juan Fernando Ortíz, Khurana M., Licata S., Nepal G., Ojha R., Pudasainee P., Quiñonez J., Rehrig J.H., Ruxmohan S., Shing Y.K., Stien J.
